Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Olanzapine Intranasal Spray (NRL-4) vs IM in Healthy Adults
NCT06600477Phase 1Completed
- Sponsor
- Neurelis
- Start
- Oct 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olanzapine in schizophrenia, schizoaffective disorder and bipolar I disorder (3 arms), sponsored by Neurelis. Primary endpoint: Area Under the Curve from time 0 to time t at 240 hours. Started Oct 2023; status: completed.
02
Drugs
olanzapine
03
Conditions
schizophreniaschizoaffective disorderbipolar I disorder
Beyond the preview
Go deeper on NCT06600477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600477.